by: Parent Project Muscular Dystrophy
Sarepta Therapeutics recently joined PPMD for a community webinar: Data Update From the MOMENTUM Study of SRP-5051. Sarepta Therapeutics was invited to share data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in people living with Duchenne muscular dystrophy who are amenable to skipping exon 51.
Sarepta shared efficacy findings, noting that MOMENTUM Part B met the primary endpoint of an increase in dystrophin expression from baseline to Week 28. With regards to safety, Sarepta noted that there were no treatment-related discontinuations of the study and the data suggest that the benefits of treatment with SRP-5051 outweigh any risks. The Sarepta team answered questions from the community on a variety of topics, as well as touched on the company’s plans for next steps for discussions with FDA.
